title: Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
abstract: Organic anion transporting polypeptide (Oatp) 1a/1b knockout and OATP1B1 and -1B3 humanized mouse models are promising tools for studying the roles of these transporters in drug disposition. Detailed characterization of these models will help to better understand their utility for predicting clinical outcomes. To advance this approach, we carried out a comprehensive analysis of these mouse lines by evaluating the compensatory changes in mRNA expression, quantifying the amounts of OATP1B1 and -1B3 protein by liquid chromatography-tandem mass spectrometry, and studying the active uptake in isolated hepatocytes and the pharmacokinetics of some prototypical substrates including statins. Major outcomes from these studies were 1) mostly moderate compensatory changes in only a few genes involved in drug metabolism and disposition, 2) a robust hepatic expression of OATP1B1 and -1B3 proteins in the respective humanized mouse models, and 3) functional activities of the human transporters in hepatocytes isolated from the humanized models with several substrates tested in vitro and with pravastatin in vivo. However, the expression of OATP1B1 and -1B3 in the humanized models did not significantly alter liver or plasma concentrations of rosuvastatin and pitavastatin compared with Oatp1a/1b knockout controls under the conditions used in our studies. Hence, although the humanized OATP1B1 and -1B3 mice showed in vitro and/or in vivo functional activity with some statins, further characterization of these models is required to define their potential use and limitations in the prediction of drug disposition and drug-drug interactions in humans.
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Laurent
authors.initials: L
authors.lastname: Salphati
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Chu
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Liangfu
authors.initials: L
authors.lastname: Chen
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Bhagwat
authors.initials: B
authors.lastname: Prasad
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Shannon
authors.initials: S
authors.lastname: Dallas
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Raymond
authors.initials: R
authors.lastname: Evers
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Donna
authors.initials: D
authors.lastname: Mamaril-Fishman
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Ethan G
authors.initials: EG
authors.lastname: Geier
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kehler
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Jeevan
authors.initials: J
authors.lastname: Kunta
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Mario
authors.initials: M
authors.lastname: Mezler
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Loic
authors.initials: L
authors.lastname: Laplanche
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Jodie
authors.initials: J
authors.lastname: Pang
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Anja
authors.initials: A
authors.lastname: Rode
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Soars
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Jashvant D
authors.initials: JD
authors.lastname: Unadkat
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Robert A B
authors.initials: RA
authors.lastname: van Waterschoot
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Yabut
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.).
authors.forename: Alfred H
authors.initials: AH
authors.lastname: Schinkel
authors.affiliation: DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.) nico.scheer@taconicartemis.com.
authors.forename: Nico
authors.initials: N
authors.lastname: Scheer
mesh_terms: D000818:Animals; D004347:Drug Interactions / Q000502:physiology; D005464:Fluorobenzenes / Q000378:metabolism; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism*; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D027381:Liver-Specific Organic Anion Transporter 1; D008297:Male; D051379:Mice; D027361:Organic Anion Transporters / Q000378:metabolism*; D029362:Organic Anion Transporters, Sodium-Independent / Q000378:metabolism*; D017035:Pravastatin / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D000068718:Rosuvastatin Calcium; D000074542:Solute Carrier Organic Anion Transporter Family Member 1B3; D013449:Sulfonamides / Q000378:metabolism
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; D029362:Organic Anion Transporters, Sodium-Independent; D011743:Pyrimidines; D012333:RNA, Messenger; C503999:SLCO1B1 protein, human; C421209:SLCO1B3 protein, human; D000074542:Solute Carrier Organic Anion Transporter Family Member 1B3; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D017035:Pravastatin